News

The development and qualification of biomarkers are keys to the future of drug development and precision medicine, particularly in oncology.

Challenges faced by researchers conducting clinical trials in low- and middle-income countries are examined.

Results from a Clinical SCORE study shows investigators and other site staff are begging sponsors and CROs to match their tenacity to soldier on.

COVID-19 response is leading to new measures being introduced in many countries, including Russia, Europe and CIS countries, especially when it comes to the interaction of research centers with CRAs.

Sponsors need to develop a strategy on how to evaluate the impact of the pandemic on the re-start of halted trials.

Tufts Center for the Study of Drug Development and Biogen recently conducted a study to inform growing interest in improving diversity of clinical trial participation. The results of this research provide insights into increasing the community of minority investigators and study staff and presenting greater access to clinical trials among minority study volunteers.

Following the implement of new Drug Registration Regulation in July 2020, the clinical trial registration system will have some major changes in China.

Leveraging approaches in RBQM to enable effective corrective and preventive action processes.

Implementing centralized risk-based monitoring can help meet strict GCP requirements for study conduct, oversight, and recording.

Regulators are urging the use of data monitoring committees to support clinical trial management and decision-making during pandemic.

The latest happenings in the industry, all in one place.

Virtual trials tools are usually selected early in the protocol development stage, however, due to the COVID-19 crisis, regulators are encouraging sponsors to consider integrating virtual elements into clinical trials already in progress.